Novel combination achieves 60.8% response rate and 90.2% disease control rate in first-line non-small cell lung cancer (1L ...

An opinion piece written by Dr Mhairi Morris from School of Sport, Exercise and Health Sciences for The Conversation platform ...

Row Zero, the enterprise spreadsheet built for big data and security, announced a seed round of $10M, led by IA Ventures, with participation from Trilogy Equity Partners, Founder's Co-op, Ludlow ...

Chemistry professor Chris Chang’s lab studies the chemical biology of the elements, specifically examining the roles that ...

Author Table of Contents Media Contact For general and media inquiries and to book our experts, please contact: ...

Revenue of $18.0 million, an increase of 21% over Q1 2024; Gross margins of 79.4% for Q1 2025; Q1 2025 Net loss improved by 18% compared to Q1 2024; Updated 2025 Revenue Guidance to a range ...

Both charities will share the total funds raised by the firm throughout 2025 from a programme of fundraising events and ...

The U.S. Food and Drug Administration has approved AbbVie's drug to treat adults with a type of lung cancer who have received ...

Gastroesophageal reflux disease (GERD) is associated with a significant increase in the risk for lung cancer, according to study results presented at Digestive Disease Week (DDW), held May 3 to 6, ...

The FDA granted accelerated approval to telisotuzumab vedotin (Emrelis) for the treatment of adults with previously treated, ...

Kuick Research Report Gives Detailed Insight On Ongoing Rare Disease Drug Market And Highlights Ongoing Clinical TrialsDelhi, ...

These results may help guide management strategies and prognostication among patients with advanced NSCLC who experience severe irAE and in whom permanent ICI discontinuation is required,” the ...